NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors

The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2016-03, Vol.36 (3), p.887-897
Hauptverfasser: Kolodziej, Malgorzata A, Weischer, Cornelia, Reinges, Marcus H T, Uhl, Eberhard, Weigand, Marcus A, Schwarm, Frank P, Schänzer, Anne, Acker, Till, Quint, Karl, Uhle, Florian, Stein, Marco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 897
container_issue 3
container_start_page 887
container_title Anticancer research
container_volume 36
creator Kolodziej, Malgorzata A
Weischer, Cornelia
Reinges, Marcus H T
Uhl, Eberhard
Weigand, Marcus A
Schwarm, Frank P
Schänzer, Anne
Acker, Till
Quint, Karl
Uhle, Florian
Stein, Marco
description The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with overall (OS) and progression-free survival (PFS). Samples from 44 patients (31 males, 13 females; mean age±SD=57.4±15.7 years) with primary (n=40) or recurrent glioblastoma (n=4) were analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry, with dimensionless semiquantitative immunoreactivity score (IRS), ranging from 0-30] for expression of NDRG2 and NDRG4. Five non-tumorous autopsy brain specimens were used as controls. On the protein level, expression of NDRG2 was significantly down-regulated in glioblastoma (IRS=3.5±3.0 vs. 8.8±3.3; p=0.001), while expression of NDRG4 was significantly up-regulated (IRS=5.4±3.7 vs. 0.75±0.4 vs, p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1773808779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1773808779</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-6b973a3937c57e85f64d3db4d928722bd622a32b726db4271fbe1fa07a076e843</originalsourceid><addsrcrecordid>eNo1kNFLwzAYxIsgbk7_BcmjL4U2afM1j2POOthUdD6XdPnKImlak3S6_96qEw7uOH7cw51F0xREGkPOkkl06f17knAuCnYRTSgXMCqfRsPj3UtJibSK_KSMLL96h97rzpKVJ3MT0KEi2pLS6K420oeulb_8yjZmQLtDT14Hd9AHaX64Zxk02uDJpw57sik327jFsD8aGcah7dB2zl9F5400Hq9PPove7pfbxUO8fipXi_k67mmahpjXAphkgsEuByzyhmeKqTpTghZAaa04pZLRGigfWwppU2PayARGcSwyNotu_3Z7130M6EPVar9DY6TFbvBVCsCKpAAQI3pzQoe6RVX1TrfSHav_q9g3d_1jvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1773808779</pqid></control><display><type>article</type><title>NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kolodziej, Malgorzata A ; Weischer, Cornelia ; Reinges, Marcus H T ; Uhl, Eberhard ; Weigand, Marcus A ; Schwarm, Frank P ; Schänzer, Anne ; Acker, Till ; Quint, Karl ; Uhle, Florian ; Stein, Marco</creator><creatorcontrib>Kolodziej, Malgorzata A ; Weischer, Cornelia ; Reinges, Marcus H T ; Uhl, Eberhard ; Weigand, Marcus A ; Schwarm, Frank P ; Schänzer, Anne ; Acker, Till ; Quint, Karl ; Uhle, Florian ; Stein, Marco</creatorcontrib><description>The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with overall (OS) and progression-free survival (PFS). Samples from 44 patients (31 males, 13 females; mean age±SD=57.4±15.7 years) with primary (n=40) or recurrent glioblastoma (n=4) were analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry, with dimensionless semiquantitative immunoreactivity score (IRS), ranging from 0-30] for expression of NDRG2 and NDRG4. Five non-tumorous autopsy brain specimens were used as controls. On the protein level, expression of NDRG2 was significantly down-regulated in glioblastoma (IRS=3.5±3.0 vs. 8.8±3.3; p=0.001), while expression of NDRG4 was significantly up-regulated (IRS=5.4±3.7 vs. 0.75±0.4 vs, p&lt;0.001). There was no statistically significant difference in PFS between a group of 15 patients with glioblastoma with MGMT methylation and enhanced expression of NDRG4 mRNA who were treated with adjuvant radiochemotherapy (temozolomide and 60 Gy) and a group of patients with low expression of NDRG4 mRNA [10 (range=5.5-14.2) months vs. 21 (range=10.7-31.3) months] (p=0.13). Expression of both NDRG2 and NDRG4 genes is significantly altered in glioblastomas. PFS among the patients with glioblastoma with MGMT methylation treated with radiochemotherapy differed significantly in high-expression groups compared to patients without MGMT methlation and without radiochemotherapy (p&lt;0.05).</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 26976975</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Brain Neoplasms - genetics ; Brain Neoplasms - metabolism ; Brain Neoplasms - mortality ; Brain Neoplasms - therapy ; Chemoradiotherapy, Adjuvant ; DNA Methylation ; DNA Modification Methylases - genetics ; DNA Repair Enzymes - genetics ; Female ; Gene Expression Regulation, Neoplastic ; Glioblastoma - genetics ; Glioblastoma - metabolism ; Glioblastoma - mortality ; Glioblastoma - therapy ; Humans ; Male ; Middle Aged ; Muscle Proteins - genetics ; Muscle Proteins - metabolism ; Nerve Tissue Proteins - genetics ; Nerve Tissue Proteins - metabolism ; Prognosis ; Survival Analysis ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism</subject><ispartof>Anticancer research, 2016-03, Vol.36 (3), p.887-897</ispartof><rights>Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26976975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kolodziej, Malgorzata A</creatorcontrib><creatorcontrib>Weischer, Cornelia</creatorcontrib><creatorcontrib>Reinges, Marcus H T</creatorcontrib><creatorcontrib>Uhl, Eberhard</creatorcontrib><creatorcontrib>Weigand, Marcus A</creatorcontrib><creatorcontrib>Schwarm, Frank P</creatorcontrib><creatorcontrib>Schänzer, Anne</creatorcontrib><creatorcontrib>Acker, Till</creatorcontrib><creatorcontrib>Quint, Karl</creatorcontrib><creatorcontrib>Uhle, Florian</creatorcontrib><creatorcontrib>Stein, Marco</creatorcontrib><title>NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with overall (OS) and progression-free survival (PFS). Samples from 44 patients (31 males, 13 females; mean age±SD=57.4±15.7 years) with primary (n=40) or recurrent glioblastoma (n=4) were analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry, with dimensionless semiquantitative immunoreactivity score (IRS), ranging from 0-30] for expression of NDRG2 and NDRG4. Five non-tumorous autopsy brain specimens were used as controls. On the protein level, expression of NDRG2 was significantly down-regulated in glioblastoma (IRS=3.5±3.0 vs. 8.8±3.3; p=0.001), while expression of NDRG4 was significantly up-regulated (IRS=5.4±3.7 vs. 0.75±0.4 vs, p&lt;0.001). There was no statistically significant difference in PFS between a group of 15 patients with glioblastoma with MGMT methylation and enhanced expression of NDRG4 mRNA who were treated with adjuvant radiochemotherapy (temozolomide and 60 Gy) and a group of patients with low expression of NDRG4 mRNA [10 (range=5.5-14.2) months vs. 21 (range=10.7-31.3) months] (p=0.13). Expression of both NDRG2 and NDRG4 genes is significantly altered in glioblastomas. PFS among the patients with glioblastoma with MGMT methylation treated with radiochemotherapy differed significantly in high-expression groups compared to patients without MGMT methlation and without radiochemotherapy (p&lt;0.05).</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - therapy</subject><subject>Chemoradiotherapy, Adjuvant</subject><subject>DNA Methylation</subject><subject>DNA Modification Methylases - genetics</subject><subject>DNA Repair Enzymes - genetics</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Glioblastoma - genetics</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle Proteins - genetics</subject><subject>Muscle Proteins - metabolism</subject><subject>Nerve Tissue Proteins - genetics</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kNFLwzAYxIsgbk7_BcmjL4U2afM1j2POOthUdD6XdPnKImlak3S6_96qEw7uOH7cw51F0xREGkPOkkl06f17knAuCnYRTSgXMCqfRsPj3UtJibSK_KSMLL96h97rzpKVJ3MT0KEi2pLS6K420oeulb_8yjZmQLtDT14Hd9AHaX64Zxk02uDJpw57sik327jFsD8aGcah7dB2zl9F5400Hq9PPove7pfbxUO8fipXi_k67mmahpjXAphkgsEuByzyhmeKqTpTghZAaa04pZLRGigfWwppU2PayARGcSwyNotu_3Z7130M6EPVar9DY6TFbvBVCsCKpAAQI3pzQoe6RVX1TrfSHav_q9g3d_1jvA</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Kolodziej, Malgorzata A</creator><creator>Weischer, Cornelia</creator><creator>Reinges, Marcus H T</creator><creator>Uhl, Eberhard</creator><creator>Weigand, Marcus A</creator><creator>Schwarm, Frank P</creator><creator>Schänzer, Anne</creator><creator>Acker, Till</creator><creator>Quint, Karl</creator><creator>Uhle, Florian</creator><creator>Stein, Marco</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201603</creationdate><title>NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors</title><author>Kolodziej, Malgorzata A ; Weischer, Cornelia ; Reinges, Marcus H T ; Uhl, Eberhard ; Weigand, Marcus A ; Schwarm, Frank P ; Schänzer, Anne ; Acker, Till ; Quint, Karl ; Uhle, Florian ; Stein, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-6b973a3937c57e85f64d3db4d928722bd622a32b726db4271fbe1fa07a076e843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - therapy</topic><topic>Chemoradiotherapy, Adjuvant</topic><topic>DNA Methylation</topic><topic>DNA Modification Methylases - genetics</topic><topic>DNA Repair Enzymes - genetics</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Glioblastoma - genetics</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle Proteins - genetics</topic><topic>Muscle Proteins - metabolism</topic><topic>Nerve Tissue Proteins - genetics</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolodziej, Malgorzata A</creatorcontrib><creatorcontrib>Weischer, Cornelia</creatorcontrib><creatorcontrib>Reinges, Marcus H T</creatorcontrib><creatorcontrib>Uhl, Eberhard</creatorcontrib><creatorcontrib>Weigand, Marcus A</creatorcontrib><creatorcontrib>Schwarm, Frank P</creatorcontrib><creatorcontrib>Schänzer, Anne</creatorcontrib><creatorcontrib>Acker, Till</creatorcontrib><creatorcontrib>Quint, Karl</creatorcontrib><creatorcontrib>Uhle, Florian</creatorcontrib><creatorcontrib>Stein, Marco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolodziej, Malgorzata A</au><au>Weischer, Cornelia</au><au>Reinges, Marcus H T</au><au>Uhl, Eberhard</au><au>Weigand, Marcus A</au><au>Schwarm, Frank P</au><au>Schänzer, Anne</au><au>Acker, Till</au><au>Quint, Karl</au><au>Uhle, Florian</au><au>Stein, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2016-03</date><risdate>2016</risdate><volume>36</volume><issue>3</issue><spage>887</spage><epage>897</epage><pages>887-897</pages><eissn>1791-7530</eissn><abstract>The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with overall (OS) and progression-free survival (PFS). Samples from 44 patients (31 males, 13 females; mean age±SD=57.4±15.7 years) with primary (n=40) or recurrent glioblastoma (n=4) were analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry, with dimensionless semiquantitative immunoreactivity score (IRS), ranging from 0-30] for expression of NDRG2 and NDRG4. Five non-tumorous autopsy brain specimens were used as controls. On the protein level, expression of NDRG2 was significantly down-regulated in glioblastoma (IRS=3.5±3.0 vs. 8.8±3.3; p=0.001), while expression of NDRG4 was significantly up-regulated (IRS=5.4±3.7 vs. 0.75±0.4 vs, p&lt;0.001). There was no statistically significant difference in PFS between a group of 15 patients with glioblastoma with MGMT methylation and enhanced expression of NDRG4 mRNA who were treated with adjuvant radiochemotherapy (temozolomide and 60 Gy) and a group of patients with low expression of NDRG4 mRNA [10 (range=5.5-14.2) months vs. 21 (range=10.7-31.3) months] (p=0.13). Expression of both NDRG2 and NDRG4 genes is significantly altered in glioblastomas. PFS among the patients with glioblastoma with MGMT methylation treated with radiochemotherapy differed significantly in high-expression groups compared to patients without MGMT methlation and without radiochemotherapy (p&lt;0.05).</abstract><cop>Greece</cop><pmid>26976975</pmid><tpages>11</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1791-7530
ispartof Anticancer research, 2016-03, Vol.36 (3), p.887-897
issn 1791-7530
language eng
recordid cdi_proquest_miscellaneous_1773808779
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aged
Brain Neoplasms - genetics
Brain Neoplasms - metabolism
Brain Neoplasms - mortality
Brain Neoplasms - therapy
Chemoradiotherapy, Adjuvant
DNA Methylation
DNA Modification Methylases - genetics
DNA Repair Enzymes - genetics
Female
Gene Expression Regulation, Neoplastic
Glioblastoma - genetics
Glioblastoma - metabolism
Glioblastoma - mortality
Glioblastoma - therapy
Humans
Male
Middle Aged
Muscle Proteins - genetics
Muscle Proteins - metabolism
Nerve Tissue Proteins - genetics
Nerve Tissue Proteins - metabolism
Prognosis
Survival Analysis
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
title NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T16%3A28%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NDRG2%20and%20NDRG4%20Expression%20Is%20Altered%20in%20Glioblastoma%20and%20Influences%20Survival%20in%20Patients%20with%20MGMT-methylated%20Tumors&rft.jtitle=Anticancer%20research&rft.au=Kolodziej,%20Malgorzata%20A&rft.date=2016-03&rft.volume=36&rft.issue=3&rft.spage=887&rft.epage=897&rft.pages=887-897&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1773808779%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1773808779&rft_id=info:pmid/26976975&rfr_iscdi=true